Inhibikase Therapeutics, Inc. (IKT) shareholders
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (15.90%), Peter Kolchinsky (15.90%) and 1 more | 25,000,000 | 15.90% | 13G (passive) | Jul 10, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 14,653,994 | 9.90% | 13G (passive) amendment | Jul 29, 2026 |
| Robert Egen Atkinson Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 14,054,940 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (9.90%), ADAR1 Capital Management GP, LLC (8.50%) | 13,860,028 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Sands Frank M. Joint filing with Sands Capital Life Sciences Pulse Fund II, L.P. (9.30%), Sands Capital Alternatives, LLC (9.30%) | 13,018,965 | 9.30% | 13G (passive) amendment | Jun 30, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 12,816,643 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| ADAR1 Capital Management GP, LLC Joint filing with ADAR1 Capital Management, LLC (9.90%), Daniel Schneeberger (9.90%) | 12,692,387 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Tomas Kiselak Joint filing with Fairmount Funds Management LLC (9.90%), Fairmount Healthcare Fund II L.P. (9.90%) and 1 more | 12,461,101 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Sands Capital Life Sciences Pulse Fund II, L.P. Joint filing with Sands Capital Alternatives, LLC (14.70%), Sands Frank M. (14.70%) | 10,950,000 | 14.70% | 13G (passive) amendment | Jun 30, 2025 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (6.90%), Perceptive Life Sciences Master Fund, Ltd. (6.90%) | 10,320,875 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Ortav Yehudai Joint filing with Trails Edge Capital Partners, LP (6.10%), Trails Edge Biotechnology Master Fund, LP (6.10%) | 8,057,345 | 6.10% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 7,768,004 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Soleus Private Equity Fund III, L.P. Joint filing with Soleus Private Equity GP III, LLC (9.99%), Soleus PE GP III, LLC (9.99%) and 5 more | 7,228,908 | 9.99% | 13G (passive) | Oct 21, 2024 |
| Fairmount Funds Management LLC Joint filing with Fairmount Healthcare Fund II L.P. (9.90%), Peter Harwin (9.90%) and 1 more | 7,018,575 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Trails Edge Capital Partners, LP Joint filing with Trails Edge Biotechnology Master Fund, LP (5.10%), Ortav Yehudai (5.10%) | 6,145,198 | 5.10% | 13G (passive) | Dec 23, 2025 |
| SP Soleus Holdings LLC Joint filing with Sp Ikt Holdings LLC : 83-18418459 (8.69%) | 5,840,000 | 8.69% | 13G (passive) | Oct 21, 2024 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (7.54%), Daniel Mack (7.54%) | 5,298,624 | 7.54% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IKT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sands Capital Ventures, LLC | 13,018,965 | 9.33% | $26.43M | – | 4.31% |
| Soleus Capital Management, L.P. | 10,875,000 | 7.79% | $22.08M | – | 0.76% |
| Trails Edge Capital Partners, LP | 9,051,318 | 6.49% | $18.37M | +993,973 | 2.92% |
| Fairmount Funds Management LLC | 8,625,000 | 6.18% | $17.51M | – | 1.16% |
| BlackRock, Inc. | 7,768,057 | 5.57% | $15.77M | +1,464,624 | 0.00% |
| Kalehua Capital Management LLC | 7,643,780 | 5.48% | $15.52M | +1,149,282 | 4.95% |
| ADAR1 Capital Management, LLC | 7,387,205 | 5.29% | $15.00M | +780,633 | 0.69% |
| Blackstone Inc. | 5,938,276 | 4.26% | $12.05M | – | 0.04% |
| Siren, L.L.C. | 5,850,000 | 4.19% | $11.88M | – | 0.24% |
| Nantahala Capital Management, LLC | 5,403,726 | 3.87% | $10.97M | +2,701,863 | 0.18% |
| Commodore Capital LP | 5,397,488 | 3.87% | $10.96M | – | 0.65% |
| Vanguard Capital Management LLC | 4,935,354 | 3.54% | $10.02M | +484,689 | 0.00% |
| Millennium Management LLC | 4,028,102 | 2.89% | $8.18M | +1,100,025 | 0.00% |
| Saturn V Capital Management LP | 3,869,056 | 2.77% | $7.85M | +5,611 | 1.13% |
| Spruce Street Capital LP | 3,581,603 | 2.57% | $7.27M | – | 1.43% |
| Squadron Capital Management LLC | 3,000,000 | 2.15% | $6.09M | −500,000 | 1.89% |
| Geode Capital Management, LLC | 2,607,129 | 1.87% | $5.29M | +436,943 | 0.00% |
| State Street Corp | 1,909,101 | 1.37% | $3.88M | +223,285 | 0.00% |
| SummitTX Capital, L.P. | 1,780,262 | 1.28% | $3.61M | +255,726 | 0.09% |
| Integral Health Asset Management, LLC | 1,350,000 | 0.97% | $2.74M | – | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 106 | 124M | 89.1% | 19 / 49 | 23 / 14 | 13M | 7M |
| Q1 2026 | 104 | 118M | 84.4% | 39 / 38 | 14 / 8 | 27M | 11M |
| Q4 2025 | 74 | 106M | 76.3% | 21 / 27 | 15 / 1 | 52M | 0M |
| Q3 2025 | 54 | 55M | 39.4% | 8 / 16 | 15 / 2 | 1M | 1M |
| Q2 2025 | 48 | 55M | 39.1% | 24 / 11 | 6 / 23 | 6M | 3M |
| Q1 2025 | 47 | 51M | 36.9% | 19 / 12 | 3 / 3 | 2M | 1M |
| Q4 2024 | 31 | 50M | 35.9% | 23 / 7 | 0 / 3 | 50M | 1M |
| Q3 2024 | 11 | 1M | 0.6% | 1 / 4 | 2 / 2 | 0M | 0M |
| Q2 2024 | 12 | 1M | 0.6% | 4 / 3 | 3 / 4 | 1M | 0M |
| Q1 2024 | 12 | 0M | 0.1% | 3 / 3 | 4 / 2 | 0M | 0M |
| Q4 2023 | 11 | 0M | 0.2% | 2 / 4 | 3 / 4 | 0M | 0M |
| Q3 2023 | 13 | 0M | 0.3% | 1 / 8 | 3 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
82 funds held IKT in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IKT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,764,138 | 2.70% | $7.64M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,009,439 | 2.16% | $6.11M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,320,308 | 0.95% | $2.88M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,107,121 | 0.79% | $2.25M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,055,770 | 0.76% | $2.14M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 547,192 | 0.39% | $957.59K | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 421,326 | 0.30% | $737.32K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 406,711 | 0.29% | $825.62K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 294,004 | 0.21% | $640.93K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 236,794 | 0.17% | $480.69K | 0.01% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 215,750 | 0.15% | $437.97K | 0.00% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 171,152 | 0.12% | $347.44K | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund | 169,113 | 0.12% | $343.30K | 0.02% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 161,780 | 0.12% | $352.68K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 143,459 | 0.10% | $251.05K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark T. Iwicki | Chief Executive Officer, Director | – | – | Jan 7, 2026 |
| Milton H. Werner | President and CEO, Director | 5,359,022 | 3.84% | Jan 22, 2025 |
| Christopher Cabell | President & Head of R&D | 676,564 | 0.48% | Feb 24, 2026 |
| David McIntyre | Chief Financial Officer | 10,285 | 0.01% | Jan 7, 2026 |
| Garth Lees-Rolfe | Chief Financial Officer | – | – | Jan 22, 2025 |
| Scott M. Wasserman | Director | – | – | Oct 21, 2026 |
| Dennis N. Berman | Director | 21,854 | 0.02% | Jul 31, 2026 |
| David Canner | Director | – | – | Jun 30, 2026 |
| Arvind Kush | Director | 145,000 | 0.10% | Jun 30, 2026 |
| Vincent Aurentz | Director | 510,596 | 0.37% | Jun 30, 2026 |
| Amit Munshi | Director | 403,176 | 0.29% | Jun 30, 2026 |
| Roberto Bellini | Director | 1,460,000 | 1.05% | Jun 30, 2026 |
| Roy Lester Freeman | Director | – | – | Feb 19, 2025 |
| Capital Healthcare Fund LP RA | 10% owner | 6,970,000 | 5.00% | Jul 31, 2026 |
| Ra Capital Management, L.P. | 10% owner | – | – | Jul 31, 2026 |
| Peter Kolchinsky | 10% owner | – | – | Jul 31, 2026 |
| Rajeev M. Shah | 10% owner | – | – | Jul 31, 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10% owner | – | – | Nov 24, 2025 |
| Sands Capital Alternatives, LLC | 10% owner | 10,950,000 | 7.85% | Nov 24, 2025 |
| Frank M. Sands | 10% owner | 13,018,965 | 9.33% | Nov 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dennis N. Berman Director | Jul 30, 2026 | Option exercise | +21,854 | $1.26 | $27.54K | 21,854 |
| Capital Healthcare Fund LP RA 10% owner | Jul 29, 2026 | Other | −18,030,000 | – | – | 6,970,000 |
| Vincent Aurentz Director | Feb 21, 2026 | Returned to company | −255,299 | – | – | 510,596 |
| Christopher Cabell President & Head of R&D | Feb 21, 2026 | Returned to company | −338,282 | – | – | 676,564 |
| Amit Munshi Director | Feb 21, 2026 | Returned to company | −19,089 | – | – | 38,176 |
| Frank M. Sands 10% owner | Nov 21, 2025 | Buy | +2,068,965 | $1.45 | $3.00M | 13,018,965 |
| Amit Munshi Director | Feb 21, 2025 | Award | +57,265 | – | – | 57,265 |
| Roberto Bellini Director | Oct 21, 2024 | Buy | +1,460,000 | $1.37 | $2.00M | 1,460,000 |
| Amit Munshi Director | Oct 21, 2024 | Buy | +365,000 | $1.37 | $500.05K | 365,000 |
| Arvind Kush Director | Oct 21, 2024 | Buy | +145,000 | $1.37 | $198.65K | 145,000 |
| Milton H. Werner President and CEO, Director, 10% owner | Aug 16, 2022 | Buy | +5,000 | $0.80 | $4.00K | 5,335,433 |
| Milton H. Werner President and CEO, Director, 10% owner | May 27, 2022 | Buy | +5,000 | $0.98 | $4.90K | 5,330,433 |
| Milton H. Werner President and CEO, Director, 10% owner | May 20, 2022 | Buy | +10,000 | $0.60 | $6.00K | 5,325,433 |
| Joseph Frattaroli Chief Financial Officer | May 19, 2022 | Buy | +3,948 | $0.64 | $2.53K | 48,091 |
| Milton H. Werner President and CEO, Director, 10% owner | Jan 3, 2022 | Option exercise | +21,853 | $2.02 | $44.14K | 5,315,433 |
| Milton H. Werner President and CEO, Director, 10% owner | Nov 17, 2021 | Buy | +1,100 | $1.97 | $2.17K | 23,589 |
| Milton H. Werner President and CEO, Director, 10% owner | Nov 17, 2021 | Buy | +17,569 | $1.98 | $34.79K | 23,589 |
| Milton H. Werner President and CEO, Director, 10% owner | Nov 17, 2021 | Buy | +1,334 | $1.94 | $2.59K | 23,589 |
| Milton H. Werner President and CEO, Director, 10% owner | Nov 17, 2021 | Buy | +400 | $1.93 | $772 | 23,589 |
| Milton H. Werner President and CEO, Director, 10% owner | Nov 17, 2021 | Buy | +3,186 | $1.96 | $6.24K | 23,589 |
| Milton H. Werner President and CEO, Director, 10% owner | Aug 17, 2021 | Option exercise | +21,853 | $2.02 | $44.14K | 5,293,580 |
| Milton H. Werner President and CEO, Director, 10% owner | May 14, 2021 | Tax withholding | −16,918 | $4.59 | $77.65K | 5,271,727 |
| Milton H. Werner President and CEO, Director, 10% owner | May 14, 2021 | Option exercise | +43,707 | $0.38 | $16.61K | 5,288,645 |
| Joseph Frattaroli Chief Financial Officer | Dec 28, 2020 | Conversion | +44,143 | $10.00 | $441.43K | 44,143 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inhibikase Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,166 shares on Sep 10, 2026 over the last 90 days.
See a number that looks wrong?